Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dmb-3115
- Development stage
- Approved
- Lead developer
- Dong-A ST
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
DMB-3115 is a biosimilar to ustekinumab (Stelara), a recombinant monoclonal antibody targeting interleukin 12 and interleukin 23. It is developed for the treatment of several autoimmune diseases including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The drug was jointly developed by Dong-A Socio Holdings and Meiji Seika Pharma under a strategic partnership initiated in 2011. Intas Pharmaceuticals holds exclusive commercialization rights outside certain Asian countries; its subsidiaries Accord BioPharma (US) and Accord Healthcare (Europe) are responsible for regional commercialization. Clinical trials have demonstrated high similarity between DMB-3115 and reference ustekinumab in terms of quality, safety, efficacy, pharmacokinetics, and immunogenicity[2][4][6][7][9].
- Brand names
- ImuldosaAbsimky
- Other names
- DMB 3115DMB3115DMB-3115ImuldosaAbsimky
02
Targets
IL12B (Interleukin-12/23 p40 subunit)
Beyond the preview
Go deeper on dmb-3115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dmb-3115.